Status:
ACTIVE_NOT_RECRUITING
Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
IVF
Intracytoplasmic Sperm Injection
Eligibility:
FEMALE
Up to 42 years
Phase:
NA
Brief Summary
To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high uterine contraction frequency prior to embryo transfer has a higher live birth rate.
Eligibility Criteria
Inclusion
- \- Women undergoing embryo transfer in either fresh or frozen cycles
Exclusion
- Women aged \> 42 years old
- Women with factors which will affect uterine contractility
- congenital uterine anomaly
- acquired uterine pathology such as myoma \>5cm, adenomyosis \>5cm or endometrial polyp
- Women with presence of hydrosalpinx
- Women undergoing pre-implantation genetic test in IVF cycles
- History of allergy to misoprostol , Buscopan® or same group of drug
- Contraindication to the use of Buscopan® e.g. glaucoma, myasthenia gravis, tachycardia, megacolon
- Women who are on other smooth muscle relaxant other than Buscopan®
Key Trial Info
Start Date :
May 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 14 2024
Estimated Enrollment :
675 Patients enrolled
Trial Details
Trial ID
NCT04751084
Start Date
May 30 2020
End Date
September 14 2024
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong